BRPI0613146B8 - uso terapêutico de inibidores de src quinase - Google Patents
uso terapêutico de inibidores de src quinaseInfo
- Publication number
- BRPI0613146B8 BRPI0613146B8 BRPI0613146A BRPI0613146A BRPI0613146B8 BR PI0613146 B8 BRPI0613146 B8 BR PI0613146B8 BR PI0613146 A BRPI0613146 A BR PI0613146A BR PI0613146 A BRPI0613146 A BR PI0613146A BR PI0613146 B8 BRPI0613146 B8 BR PI0613146B8
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- bone
- limited
- arthritis
- kinase inhibitors
- Prior art date
Links
- 102000001332 SRC Human genes 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 108010087686 src-Family Kinases Proteins 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010005949 Bone cancer Diseases 0.000 abstract 2
- 208000018084 Bone neoplasm Diseases 0.000 abstract 2
- 208000003076 Osteolysis Diseases 0.000 abstract 2
- 206010003246 arthritis Diseases 0.000 abstract 2
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 2
- 208000029791 lytic metastatic bone lesion Diseases 0.000 abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000000901 Focal Epithelial Hyperplasia Diseases 0.000 abstract 1
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 201000002980 Hyperparathyroidism Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 208000019664 bone resorption disease Diseases 0.000 abstract 1
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 208000030915 hypercalcemia disease Diseases 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000399 orthopedic effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
inibição de lesões osteolíticas por inibidores de src quinase. a presente invenção incluí métodos e composições para tratar doenças de reabsorção óssea ou reabsorção óssea relacionada a uma condição patológica incluindo, geralmente, mas sem limitação, osteoporose, artrite, artrite reumatôlde, metástase de câncer para o osso, câncer ósseo, hipercalcemia, lesões osteolíticas com implantes ortopédicos, doença de paget, e perda óssea associada ao hiperparatiroidismo. cânceres representativos incluem, mas sem limitação, câncer da mama, câncer da próstata, câncer do cólon, câncer do endométrio, mieloma múltiplo, carcinoma de células renais, doença de heck, cânceres do pescoço e da cabeça, e carcinoma cervical. condições artríticas incluem, mas sem limitação, artrite induzida por adjuvante, colágeno, bactéria e antígeno, particularmente artrite reumatóide.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69193305P | 2005-06-17 | 2005-06-17 | |
| US60/691,933 | 2005-06-17 | ||
| PCT/US2006/023529 WO2006138590A1 (en) | 2005-06-17 | 2006-06-16 | Inhibition of osteolytic lesions by src kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0613146A2 BRPI0613146A2 (pt) | 2010-12-21 |
| BRPI0613146B1 BRPI0613146B1 (pt) | 2020-08-11 |
| BRPI0613146B8 true BRPI0613146B8 (pt) | 2021-05-25 |
Family
ID=37570781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0613146A BRPI0613146B8 (pt) | 2005-06-17 | 2006-06-16 | uso terapêutico de inibidores de src quinase |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7468379B2 (pt) |
| EP (1) | EP1896020B1 (pt) |
| JP (1) | JP5121706B2 (pt) |
| KR (2) | KR20140036336A (pt) |
| CN (2) | CN101242835A (pt) |
| AU (1) | AU2006259243B2 (pt) |
| BR (1) | BRPI0613146B8 (pt) |
| CA (1) | CA2612333C (pt) |
| DK (1) | DK1896020T3 (pt) |
| ES (1) | ES2509875T3 (pt) |
| HK (1) | HK1116087A1 (pt) |
| IL (1) | IL188146A (pt) |
| MX (1) | MX2007016230A (pt) |
| NZ (1) | NZ564507A (pt) |
| PL (1) | PL1896020T3 (pt) |
| PT (1) | PT1896020E (pt) |
| SI (1) | SI1896020T1 (pt) |
| WO (1) | WO2006138590A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109953986A (zh) * | 2019-04-04 | 2019-07-02 | 泉州师范学院 | 一种小分子抑制剂azin53及其在制药中的应用 |
| WO2021245677A1 (en) * | 2020-06-05 | 2021-12-09 | Digestix Bioscience Inc. | Compositions and methods for treating dysplastic and early-stage neoplastic conditions |
| WO2024054793A1 (en) * | 2022-09-09 | 2024-03-14 | University Of Rochester | Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| JPH10287679A (ja) * | 1997-04-11 | 1998-10-27 | Takeda Chem Ind Ltd | Ｔａｎ−２４８３関連化合物、その製造法および用途 |
| IL150061A0 (en) * | 1999-12-17 | 2002-12-01 | Ariad Pharma Inc | Purine derivatives |
| IL150059A0 (en) * | 1999-12-17 | 2002-12-01 | Ariad Pharma Inc | Novel heterocycles |
| US20030045480A1 (en) | 2001-07-09 | 2003-03-06 | Pavel Safar | Method of treating hyperresorptive bone disorders |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| JP2005008581A (ja) * | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| JP2005089352A (ja) * | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| RU2006113691A (ru) | 2003-11-06 | 2007-12-20 | Вайет (Us) | Применение 4-анилин-3-хинолинкарбонитрилов для лечения хронической миелогенной лейкемии (cml) |
-
2006
- 2006-06-16 WO PCT/US2006/023529 patent/WO2006138590A1/en active Application Filing
- 2006-06-16 PL PL06773373T patent/PL1896020T3/pl unknown
- 2006-06-16 KR KR1020147006206A patent/KR20140036336A/ko not_active Application Discontinuation
- 2006-06-16 EP EP06773373.3A patent/EP1896020B1/en active Active
- 2006-06-16 BR BRPI0613146A patent/BRPI0613146B8/pt active IP Right Grant
- 2006-06-16 ES ES06773373.3T patent/ES2509875T3/es active Active
- 2006-06-16 CN CNA2006800297469A patent/CN101242835A/zh active Pending
- 2006-06-16 CA CA2612333A patent/CA2612333C/en active Active
- 2006-06-16 PT PT67733733T patent/PT1896020E/pt unknown
- 2006-06-16 NZ NZ564507A patent/NZ564507A/en unknown
- 2006-06-16 SI SI200631836T patent/SI1896020T1/sl unknown
- 2006-06-16 CN CN201310562417.2A patent/CN103705517A/zh active Pending
- 2006-06-16 DK DK06773373.3T patent/DK1896020T3/da active
- 2006-06-16 US US11/455,272 patent/US7468379B2/en active Active
- 2006-06-16 KR KR1020087001393A patent/KR101385488B1/ko active IP Right Grant
- 2006-06-16 JP JP2008517161A patent/JP5121706B2/ja active Active
- 2006-06-16 AU AU2006259243A patent/AU2006259243B2/en active Active
- 2006-06-16 MX MX2007016230A patent/MX2007016230A/es active IP Right Grant
-
2007
- 2007-12-13 IL IL188146A patent/IL188146A/en active IP Right Grant
-
2008
- 2008-08-26 HK HK08109456.0A patent/HK1116087A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101242835A (zh) | 2008-08-13 |
| MX2007016230A (es) | 2008-03-06 |
| WO2006138590A1 (en) | 2006-12-28 |
| DK1896020T3 (da) | 2014-10-27 |
| IL188146A0 (en) | 2008-06-05 |
| BRPI0613146A2 (pt) | 2010-12-21 |
| PT1896020E (pt) | 2014-10-28 |
| NZ564507A (en) | 2010-12-24 |
| JP5121706B2 (ja) | 2013-01-16 |
| US20070004748A1 (en) | 2007-01-04 |
| CA2612333C (en) | 2013-12-17 |
| EP1896020A4 (en) | 2010-11-24 |
| AU2006259243B2 (en) | 2011-04-21 |
| HK1116087A1 (en) | 2008-12-19 |
| SI1896020T1 (sl) | 2014-11-28 |
| PL1896020T3 (pl) | 2015-02-27 |
| CN103705517A (zh) | 2014-04-09 |
| BRPI0613146B1 (pt) | 2020-08-11 |
| ES2509875T3 (es) | 2014-10-20 |
| KR20080030025A (ko) | 2008-04-03 |
| JP2008543870A (ja) | 2008-12-04 |
| EP1896020A1 (en) | 2008-03-12 |
| CA2612333A1 (en) | 2006-12-28 |
| KR101385488B1 (ko) | 2014-04-15 |
| KR20140036336A (ko) | 2014-03-25 |
| EP1896020B1 (en) | 2014-08-20 |
| IL188146A (en) | 2016-04-21 |
| US7468379B2 (en) | 2008-12-23 |
| AU2006259243A1 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY31397A1 (es) | Inhibidores de quinasa c-fms | |
| CY1121922T1 (el) | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης | |
| HK1148783A1 (zh) | 用於乳房腺的預後的基因表達標記 | |
| MXPA05013977A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
| EP2130926A3 (en) | Phage microarray profiling of the humoral response to disease | |
| NO20072489L (no) | Inhibitorer av C-FMS-kinase | |
| GB2446084A (en) | Synthesis of four color 3-o-allyl modified photocleavable fluorescent nucleotides and related methods | |
| CL2012000755A1 (es) | Compuestos especificos 2-(3-amino-1-(2,4-difluorofenil)-1h-1,2,4-triazol-5-il)-n-metil-4,5-dihidrobenzeno(b) tieno(2,3-d)oxepina-8-carboxamida, inhibidor de la ctividad de la quinasa p13; composicon farmaceutica que lo comprende; kit farmaceutico que incluye a la composicion, y su uso para el tratamiento o profilaxis del cancer. | |
| GB0521621D0 (en) | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases | |
| TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
| MX2020014234A (es) | Variantes derivadas de actriib y usos de las mismas. | |
| TNSN08396A1 (en) | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual | |
| BRPI0613146B8 (pt) | uso terapêutico de inibidores de src quinase | |
| WO2009087462A3 (en) | Ephrin type-a receptor 10 protein | |
| CY1114877T1 (el) | Παραγωγα φαινυλ πυραζολιου | |
| AU2003217397A8 (en) | Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer | |
| HUP0303563A2 (hu) | Ösztrogén receptor modulátorok | |
| WO2005000858A3 (en) | Bisphosphonate complexes | |
| GB2473579A (en) | Stat3 and TYK2 as drug targets for neurodegenerative diseases | |
| WO2003105773A3 (en) | MUTATIONS OF PDGFRA ACTIVATED AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS | |
| BR0311146A (pt) | Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino | |
| DE60228616D1 (de) | Verwendung von anastrozol zur behandlung von postmenopausalen frauen mit frühzeitigem brustkrebs | |
| PL1954830T3 (pl) | Sposoby i zestawy do prognozowania przebiegu raka sutka | |
| WO2007137149A3 (en) | Use of cathepsin k antagonists in bone production | |
| BRPI0507718A (pt) | derivados de pirazolina úteis para o tratamento de cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |